A2aR & Immunotherapy
The great need for treatments and the promise of cures are driving the search for second-generation immunotherapies beyond therapeutic antibodies targeting PD-1 and CTLA4 pathways. Immunotherapies are not limited to just therapeutic antibodies . Small-molecule inhibitors are showing great promise in clinical trials. For example, inhibitors targeting the enzymatic pathways, such as tryptophan catabolism are in late-phase clinical develop...
CD39 & CD73: Adenosine Signaling
Therapeutic antibodies targeting checkpoint receptors such as PD-1 and CTLA4 are giving new hope to cancer patients. However, not all patients respond to treatment and the search for effective co-therapies is driving substantial research. Two critical enzymes of this pathway, CD39 and CD73 , are promising targets for increasing the effectiveness of checkpoint-based immunotherapies. 1
The hydrolysis of extracellular ATP to AMP is...
